The interaction of nogalamycin and analogs with DNA and other biopolymers.
作者信息
Krueger W C, Pschigoda L M, Schpok S L, Moscowitz A, McGovren J P, Neta P, Merritt M V, Li L H
出版信息
Chem Biol Interact. 1981 Jul;36(1):1-18. doi: 10.1016/0009-2797(81)90025-9.
PMID:7249146
Abstract
摘要
相似文献
1
The interaction of nogalamycin and analogs with DNA and other biopolymers.
Chem Biol Interact. 1981 Jul;36(1):1-18. doi: 10.1016/0009-2797(81)90025-9.
2
Evidence of different binding sites for nogalamycin in DNA revealed by association kinetics.
Biochim Biophys Acta. 1984 Nov 28;802(2):162-8. doi: 10.1016/0304-4165(84)90157-0.
3
Kinetics of dissociation of nogalamycin from DNA: comparison with other anthracycline antibiotics.
Biochim Biophys Acta. 1985 Jul 5;840(3):383-92. doi: 10.1016/0304-4165(85)90219-3.
4
Template specificity of DNA binding by nogalamycin and its analogs utilizing competitive fluorescence polarization.
Cancer Res. 1981 Jun;41(6):2235-40.
5
Comparative biological and biochemical effects of nogalamycin and its analogs on L1210 leukemia.
Cancer Res. 1979 Dec;39(12):4816-22.
6
A premelting conformational transition in poly(dA)-Poly(dT) coupled to daunomycin binding.
Biochemistry. 1989 Mar 7;28(5):1993-2000. doi: 10.1021/bi00431a006.
7
Structure--activity relationships of nogalamycin analogues.
J Med Chem. 1982 May;25(5):560-7. doi: 10.1021/jm00347a016.
8
9
Improved antitumor activity by modification of nogalamycin.
J Nat Prod. 1979 Nov-Dec;42(6):569-82. doi: 10.1021/np50006a002.
10
Cellular pharmacology of 7(R)-O-methylnogarol: a new anticancer agent.
J Pharmacol Exp Ther. 1979 Aug;210(2):229-36.
引用本文的文献
1
A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.
Invest New Drugs. 1993 Feb;11(1):17-27. doi: 10.1007/BF00873906.
2
Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia.
Invest New Drugs. 1993 Nov;11(4):313-22. doi: 10.1007/BF00874430.
3
Menogaril: a new anthracycline agent entering clinical trials.
Invest New Drugs. 1984;2(4):359-67. doi: 10.1007/BF00171586.
4
A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group study.
Invest New Drugs. 1990 Aug;8(3):295-7. doi: 10.1007/BF00171840.
5
Menogaril, an anthracycline compound with a novel mechanism of action: cellular pharmacology.
Jpn J Cancer Res. 1990 Aug;81(8):842-9. doi: 10.1111/j.1349-7006.1990.tb02654.x.
6
Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).
Invest New Drugs. 1990;8 Suppl 1:S69-71.
7
Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study.
Invest New Drugs. 1991 Feb;9(1):73-5. doi: 10.1007/BF00194549.
8
Menogaril, an anthracycline derivative, inhibits DNA topoisomerase II by stabilizing cleavable complexes.
Jpn J Cancer Res. 1992 Sep;83(9):1018-23. doi: 10.1111/j.1349-7006.1992.tb02016.x.
Zotero 插件